These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25684345)

  • 1. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
    LoRusso PM; Goncalves PH; Casetta L; Carter JA; Litwiler K; Roseberry D; Rush S; Schreiber J; Simmons HM; Ptaszynski M; Sausville EA
    Invest New Drugs; 2015 Apr; 33(2):440-9. PubMed ID: 25684345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
    Khoury HJ; Garcia-Manero G; Borthakur G; Kadia T; Foudray MC; Arellano M; Langston A; Bethelmie-Bryan B; Rush S; Litwiler K; Karan S; Simmons H; Marcus AI; Ptaszynski M; Kantarjian H
    Cancer; 2012 Jul; 118(14):3556-64. PubMed ID: 22139909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.
    Infante JR; Patnaik A; Verschraegen CF; Olszanski AJ; Shaheen M; Burris HA; Tolcher AW; Papadopoulos KP; Beeram M; Hynes SM; Leohr J; Lin AB; Li LQ; McGlothlin A; Farrington DL; Westin EH; Cohen RB
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):315-326. PubMed ID: 28097385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
    Shah JJ; Kaufman JL; Zonder JA; Cohen AD; Bensinger WI; Hilder BW; Rush SA; Walker DH; Tunquist BJ; Litwiler KS; Ptaszynski M; Orlowski RZ; Lonial S
    Cancer; 2017 Dec; 123(23):4617-4630. PubMed ID: 28817190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors.
    Wakui H; Yamamoto N; Kitazono S; Mizugaki H; Nakamichi S; Fujiwara Y; Nokihara H; Yamada Y; Suzuki K; Kanda H; Akinaga S; Tamura T
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):15-23. PubMed ID: 24752449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors.
    Infante JR; Kurzrock R; Spratlin J; Burris HA; Eckhardt SG; Li J; Wu K; Skolnik JM; Hylander-Gans L; Osmukhina A; Huszar D; Herbst RS
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):165-72. PubMed ID: 21638123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.
    Holen K; DiPaola R; Liu G; Tan AR; Wilding G; Hsu K; Agrawal N; Chen C; Xue L; Rosenberg E; Stein M
    Invest New Drugs; 2012 Jun; 30(3):1088-95. PubMed ID: 21424701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
    Holen KD; Belani CP; Wilding G; Ramalingam S; Volkman JL; Ramanathan RK; Vasist LS; Bowen CJ; Hodge JP; Dar MM; Ho PT
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):447-54. PubMed ID: 20461380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
    Chari A; Htut M; Zonder JA; Fay JW; Jakubowiak AJ; Levy JB; Lau K; Burt SM; Tunquist BJ; Hilder BW; Rush SA; Walker DH; Ptaszynski M; Kaufman JL
    Cancer; 2016 Nov; 122(21):3327-3335. PubMed ID: 27433944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
    Burris HA; Jones SF; Williams DD; Kathman SJ; Hodge JP; Pandite L; Ho PT; Boerner SA; Lorusso P
    Invest New Drugs; 2011 Jun; 29(3):467-72. PubMed ID: 20069338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
    Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
    Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.
    Hollebecque A; Deutsch E; Massard C; Gomez-Roca C; Bahleda R; Ribrag V; Bourgier C; Lazar V; Lacroix L; Gazzah A; Varga A; de Baere T; Beier F; Kroesser S; Trang K; Zenke FT; Klevesath M; Soria JC
    Invest New Drugs; 2013 Dec; 31(6):1530-8. PubMed ID: 24077982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Filanesib for the treatment of multiple myeloma.
    Algarín EM; Hernández-García S; Garayoa M; Ocio EM
    Expert Opin Investig Drugs; 2020 Jan; 29(1):5-14. PubMed ID: 31815551
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
    Cervantes A; Elez E; Roda D; Ecsedy J; Macarulla T; Venkatakrishnan K; Roselló S; Andreu J; Jung J; Sanchis-Garcia JM; Piera A; Blasco I; Maños L; Pérez-Fidalgo JA; Fingert H; Baselga J; Tabernero J
    Clin Cancer Res; 2012 Sep; 18(17):4764-74. PubMed ID: 22753585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
    Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
    Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
    Hofheinz RD; Al-Batran SE; Hochhaus A; Jäger E; Reichardt VL; Fritsch H; Trommeshauser D; Munzert G
    Clin Cancer Res; 2010 Sep; 16(18):4666-74. PubMed ID: 20682708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
    Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD
    Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
    Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
    Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.